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Abstract
Background: In an adaptive trial, the researcher may have the option of responding to interim safety and efficacy data in a number of
ways, including narrowing the study focus or increasing the number of subjects, balancing treatment allocation or different forms
of randomization based on responses of subjects prior to treatment. This research aims at compiling the technical, statistical, and
regulatory implications of the employment of adaptive design in a clinical trial. Methods: Review of adaptive design clinical trials in
Medline, PubMed, EU Clinical Trials Register, and ClinicalTrials.gov. Phase I and seamless phase I/II trials were excluded. We
selected variables extracted from trials that included basic study characteristics, adaptive design features, size and use of inde-
pendent data-monitoring committees (DMCs), and blinded interim analysis. Results: The research retrieved 336 results, from
which 78 were selected for analysis. Sixty-seven were published articles, and 11 were guidelines, papers, and regulatory bills. The
most prevalent type of adaptation was the seamless phase II/III design 23.1%, followed by adaptive dose progression 19.2%, pick
the winner / drop the loser 16.7%, sample size re-estimation 10.3%, change in the study objective 9.0%, adaptive sequential design
9.0%, adaptive randomization 6.4%, biomarker adaptive design 3.8%, and endpoint adaptation 2.6%. Discussion: It is possible to infer
that the use of Adaptive Design is an ethical and scientific advantage when properly planned and applied, since it increases the
flexibility of the trial, shortens the overall clinical investigation time of a drug, and reduces the risk of patient exposure to adverse
effects related to the experimental drug. Its greater methodologic and analytic complexity requires an adequate statistical
methodology. Conclusions: The application of “adaptive clinical designs” for phase II/III studies appear to have been limited to trials
with a small number of study centers, with smaller extensions of time and to experimental drugs with more immediate clinical
effects that are amenable to risk/benefit decisions based on interim analyses. According to the reviewed studies, simple adaptive
trial designs—such as early study terminations due to futility and sample size re-estimation—are becoming widely adopted
throughout the pharmaceutical industry, especially in phase II and III studies. The pharmaceutical industry and contract research
organizations (CROs) are implementing simple adaptations more frequently and the more complex adaptations—biomarker
adaptive design, endpoint adaptation—are more sporadic.
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Introduction
In a conventional clinical trial (CT), the parameters inherent to
the study are defined in the protocol and remain unchanged
during the study. Considering several factors of uncertainty and
bias that may arise before the start of the CT (eg, target pop-
ulation change, duration of therapy, active control), a sequen-
tial design may present limitations due to erroneous
assumptions formulated in the planning phase, even if the treat-
ment under study is effective.1
The vast majority of protocols undergo changes during the
conduct of the trial. Minor alterations are introduced through
addenda to the initial protocol because they do not interfere in
the scientific and statistical validity of the initial hypothesis,
objective or endpoints. Changes that affect the validity of these
factors (major changes), as well as factors that affect human
subject rights (ability of withdrawal from the trial, protection of
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sensitive personal information, and ensured informed consent)
need validation by request of authorization to the regulatory
authorities and ethics committee.2
A major difference in an adaptive design (AD) context is
that these changes are anticipated and projected prospectively
in the protocol and/or statistical analysis plan (SAP) at the
time of its elaboration. Another characteristic inherent to this
type of design is the fact that the review and weighting of the
results of the test are done through internal data from the
study, acquired during the conduct of the study and not from
information from external sources, as results of other tests
with similar features.3
Despite the adaptations introduced in conducting the study,
it is imperative to safeguard the scientific validity of the test by
ensuring valid statistical inferences that will translate into cor-
rect results. To achieve this, operational biases need to be
minimized and it may be necessary to introduce statistical
adjustment (eg, P value adjustment or redefinition of margins
of error), which will assist in controlling type I error.
In an adaptive trial, the scientific and statistical validity is
preserved mainly by the maintenance of blinding, but also by
the prospective nature of the introduced adaptations.4
Types of Adaptive Design
The variety of possible modifications in CT design described
prospectively in the protocol (or separately, in a statistical
analysis plan [SAP]) is vast. Examples include modifications
to the following5-7:
– Criteria for inclusion in the trial (either for subsequent
inclusion in the study or for selection of a subgroup in a
patient population)
– Randomization procedure
– Treatment regimens of different study groups (eg, dose,
dosage, duration of treatment)
– Size of the study population (including cases of early
completion)
– Concomitant treatment used
– Schedule of events (eg, number of interim analysis, tim-
ing of last evaluation of the last patient and duration of
patient participation in the CT)
– Primary endpoint (eg, selection of outcome evaluation,
assessment point determination)
– Selection or addition of surrogate endpoints
– Endpoint analysis (eg, statistical methodology, control
of the type I error)
Based on the above modifications, the adaptations consid-
ered in CTs include (1) adaptive randomization, (2) adaptive
sequential design, (3) sample size re-estimation, (4) “pick the
winner,” (5) adaptive dose progression, (6) phase II/III
“seamless,” (7) biomarker adaptive design, and (8) adaptation
of trial hypothesis (Table 1).
Institutional Guidelines on Implementing an Adaptive
Design
Two guidance documents on AD have been drawn up at least in
part as a result of the pharmaceutical industry’s advocacy
efforts: the European Medicines Agency (EMA Reflection
Paper 2007)8 and the Food and Drug Administration (FDA
Draft Guidance 2010).9 The first is a relatively brief document,
focusing almost exclusively on confirmatory studies, which
neither encourages nor rules out the use of AD from a regula-
tory standpoint.
The FDA guidelines are considerably more detailed, cover-
ing both exploratory and confirmatory studies (especially on
the latter), and elucidating not only potential constraints on the
use of AD but also recommendations on how to overcome them
in the development of a new drug or medical device.9
EMA: reflection paper on adaptive design
The European Medicines Agency (EMA) Reflection Paper has
a pioneering role in the regulatory orientation of AD and has
been published at a time of intense discussion of various
aspects such as methodology, implementation, and regulatory
validation. The EMA document is not as detailed as the FDA
document and has a more limited scope, but it emphasizes
some regulatory aspects about AD that are only tangentially
discussed in the FDA document, making it a useful adjunct to
the latter.
The EMA reflection paper focuses almost exclusively on
confirmatory studies. The general guideline of the document
is to validate adaptive design and its potential usefulness, but
with clear attention to its adequate implementation in the prac-
tice of clinical research. Comparatively, it is less encouraging
about AD than the FDA document but does not neglect its use
when properly planned, conducted, and analyzed. In its initial
considerations, the EMA document recognizes that the AD has
the potential to shorten the development time of new drugs and
to allocate resources more efficiently without compromising
scientific and regulatory criteria.8
The EMA reflection paper is less didactic than the FDA
guidelines, with no attempt to classify ADs (the FDA proposes
to rank “well-understood” and “less well-understood”). A more
formal definition of AD is included on the last page of the
document and illustrates the limited view of the document:
“a study is called ‘adaptive’ if the statistical methodology
allows the modification of a design element . . . in an interim
analysis with complete control of type I error.”9 From this
definition, it becomes clear that the main concern in the doc-
ument about the validity of an AD is the control of the type I
error rate in the presence of possible adaptations.
In line with the FDA document, EMA’s review formalizes
that any step in implementing an AD must be preplanned,
adequately justified in the context of the trial developed and
kept to the minimum necessary. Tight control of type I error
rate is indicated as a prerequisite for regulatory authorization of
AD as well as use of appropriate statistical methods for
determination of therapeutic effect (P value and margin of
error) is also required.9
FDA: guidelines on implementation of adaptive design
The overall tone of the FDA guidelines is encouraging for the
application of AD, but with caution: the FDA recognizes AD as
having potential to improve the efficiency and success rate of
the development of a new drug but raises some questions about
its application in confirmatory tests. It also recognizes that the
greatest appeal of ADs is to allow preplanned interim correc-
tions throughout the trial, review study design assumptions,
and readjust endpoints based on the data obtained. Two main
points of attention are expressed at the beginning and in the
course of the guidelines: the possible inflation of the type I
error rate and the increase in operational bias, which may com-
promise the scientific integrity of the study and the validity/
interpretation of the final results.1
There are statistical methods to adequately control type I
error for a wide variety of ADs based on unblinded data (there
is less influence of type I error when adaptations are made on
blinded data), but it is emphasized that the sponsor is in order to
demonstrate analytically that statistical analysis methods will
control the type I error rate.9
Another point of discussion related to AD exposed by the
FDA is more difficult to determine and control: the potential
operational bias due to leakage of unblinded data over the
course of the trial. Changes in the population of subjects after
adaptation without blinding are cited examples of operational
bias associated with AD. Of course, such changes may also
occur when no adaptations are introduced in the trial because
they may result, for example, from the start of recruitment at
other centers at later points in the study.9
FDA guidelines explicitly support the use of AD in the
context of exploratory trials, attesting that they provide a model
for additional dose-response, subgroup-based knowledge, and
have the potential to promote substantial gains in clinical
research efficiency.
Objectives
The use of adaptive design in clinical trials has been debated
for several years and there is already regulatory documentation
on its application (FDA Guidelines and EMA Discussion
Paper) as well as medicines developed using these methods
in several countries.
Considering the amount of information available, the lim-
ited employment of adaptive design methodology in clinical
trials and the limited amount of published results in this area, it
is justified the constitution of this research as an updated body
of work to
– contextualize adaptive design in regulatory and terms of
applicability in a clinical trial;
– analyze and compare European and American (US)
guidelines;
– describe the implementation of adaptive design in a clin-
ical trial in terms of planning, subject selection, interac-
tion with regulators, and monitoring;
– describe the analysis and statistical protocol in terms of
simulation, modeling, and bias;
– to present advantages and limitations of the application
of adaptive design in clinical trials; and
– assess the future applications of adaptive design in clin-
ical trials.
Materials and Methods
Search Strategy and Eligibility Criteria
Considering the given objective, the present research is a liter-
ature review. In order to build the documental body, several
databases of specialized literature were used: ClinicalTrials.-
gov, PubMed, Medline, EU Clinical Trials Register, using the
terms Adaptive Clinical Trials, Adaptive Design, and Adaptive
Trials, with articles and publications published between 2006
and 2017.
We excluded nonhuman studies, systematic reviews, meta-
analysis, editorials, and opinion articles. Incomplete trials still
in progress were excluded to avoid misrepresenting trials,
which can sometimes change format while underway. Only
trials with adults were considered (>18 years old).
Phase I and seamless phase I/II trials we excluded because
such exploratory trials usually have low impact on regulatory
approval and/or clinical uptake of treatments.
Results
The research retrieved 336 results, from which 78 were
selected for analysis. Of those, 67 were published articles and
11 were guidelines, papers, and regulatory bills (Figure 1).
The most prevalent type of adaptation was the seamless
phase II/III design, 18/78 (23.1%); followed by adaptive dose
progression, 15/78 (19.2%); pick the winner / drop the loser,
13/78 (16.7%); sample size re-estimation, 8/78 (10.3%);
change in the study objective, 7/78 (9.0%); adaptive sequential
design, 7/78 (9.0%); adaptive randomization, 5/78 (6.4%); bio-
marker adaptive design, 3/78 (3.8%); and endpoint adaptation,
2/78 (2.6%) (Figure 2). Numerous trials incorporated more than
1 adaptation.
The selected trials were submitted under the scope of FDA
and EMA. Overall, 56/78 (71.8%) were approved without the
need of additional information submission or changes in study
protocols. Sixteen of 78 (20.5%) were required to be resub-
mitted to establish changes in study design or provide addi-
tional information regarding scientific validity of the study
according with the ADs applied. Three of 78 (3.84%) had an
approval limited to FDA regulations of AD (EMA has a more
conservative stance on AD and does not cover less used types
of AD: some types of nonvalidated biomarkers, adaptation of
endpoints, and change in study hypothesis) (Table 2).
ADs more frequently used are pick the winner / drop the
loser, phase II/III seamless, adaptive dose progression, and
adaptive sequential design, thus having a better regulatory
clearance rate. Designs like endpoint adaptation, change in
study objective, and use of AD with biomarker are still in a
more precocious stage of development that leads the
Figure 1. Flow diagram derived from preferred reporting items for systematic reviews and meta-analyses (PRISMA). This diagram reports
results of a search of published adaptive design clinical trials in PubMed on January 17, 2018, ClinicalTrials.gov on January 17, 2018, EU Clinical
Trials Register on February 23, 2018, and Medline on April 13, 2018.
Figure 2. Distribution of adaptive design type in surveyed trials per phase (n ¼ 78).
regulatory authorities to have a more cautious stance regard-
ing trials that use such ADs, which reduces their submission
clearance rate.
The selected studies include late phase II and III trials cov-
ering several therapeutic areas, which are the following: oncol-
ogy, 21/78 (26.9%); central nervous system, 15/78 (19.2%);
circulatory system disorders, 13/78 (16.7%); ophthalmology,
9/78 (11.5%); infectious diseases, 7/78 (8.9%); rheumatology,
6/78 (7.7%); dermatology, 5/78 (6.4%); and medical devices,
2/78 (2.6%) (Figure 3).
The vast majority of trials (53/78; 68%) reported industry
funding, 15/78 (19%) reported public healthcare funding, 6/78
(8%) private foundation funding, and 4/78 (5%) did not list any
funding information.
Table 1. Definition of Types of Adaptive Designs.a
Type of Adaptive Design Definition
Adaptive randomization Accumulating results are observed and the randomization scheme is adjusted so that patients enrolled later in the
trial have a higher probability of being randomized to the treatment arm that was more effective among earlier
patients in the trial.
Adaptive sequential design Results are analyzed at interim analyses, with prespecified options of making adaptations such as sample size re-
estimation, modification/deletion/addition of treatment arms, changing study endpoints, modifying dose and/or
treatment duration, or adapting randomization schedules.
Sample size re-estimation Flexible sample size adjustment or re-estimation based on interim analysis of accumulating data.
Pick the winner / drop the
loser
Possibility of dropping the inferior treatment group(s), modifying treatment arms and/or adding additional arms
based on the review of accumulating data at interim analysis.
Adaptive dose
progression
Allocation of patients to multiple different treatment doses and patient responses are assessed at interim analyses.
Trial design is then adapted to allocate more patients to the treatment doses of interest, reducing allocation of
patients to doses that appear noneffective.
Phase II/III “seamless” Combination of the objectives of the phase II investigational stage with the phase III efficacy or confirmatory stage
into a single study protocol moving from one stage to the second stage without stopping the patient enrolment
process.
Biomarker adaptive design Adaptations to the trial design based on interim analysis of the treatment responses of biomarkers, such as genomic
markers. This design can be used to select patient populations for subsequent trials, identify the natural course of
a disease, achieve early detection of a disease, and/or help in developing personalized medicine.
Adaptation of trial
hypothesis
Trial hypotheses are adapted in response to interim analysis results. They may involve a preplanned shift from a
single hypothesis to multiple hypotheses or preplanned switching between the primary and secondary study
endpoints.
aAdapted from Elsäßer et al.8
Table 2. Submission Success of Adaptive Design Trials (n ¼ 78).
Type of Adaptive Design Cleared Cleared With Resubmissiona Limited Clearanceb
Adaptive randomization 3 2 Request of independent statistical analysis plan
Adaptive sequential design 5 2 Justification of timing and frequency of interim analyses
Sample size re-estimation 6 2 Control of inflation of type I error
Pick the winner / drop the loser 12 1 Definition of efficacy and safety targets for futility
Adaptive dose progression 12 3 Adjustment of therapeutic dose regimen
Phase II/III “seamless” 16 2 Control of inflation of type I error due to inflation of sample size
Biomarker adaptive design 1 1 Request of further information for biomarker validation 1
Endpoint adaptation 1 Redefinition of rationale from superiority to non-inferiority 1
Change in study hypothesis/objective 4 2 Redefinition of rationale and therapeutic endpoints 1
Total 59 16 3
aBased on the registration and results information submission requirements described in Section 801 of the Food and Drug Administration Amendments Act of
2007 (FDAAA 801) and the Final Rule for Clinical Trials Registration and Results Information Submission (42 CFR Part 11).
bClearance only valid for FDA scope.
The sponsor profile of the selected adaptive trials is hetero-
geneous and often had multiple authors with diverse institu-
tional affiliations. Nearly all trials had at least 1 author
affiliated with an academic medical center or hospital 76/78
(97%). More than half had at least 1 author affiliated with
industry (41/78 (53%), and 17/78 (22%) had at least 1 author
affiliated with a private investigation center or foundation.
Discussion
Implementing Adaptive Design in a Clinical Trial
The various ADs cannot be implemented arbitrarily through all
types of CTs since several operational and organizational
aspects have to be considered before deciding whether adaptive
parameters are applicable and beneficial to the subjects and to
the scientific validity of the CT.
Some interim analysis may lead to the suspension of the
recruitment process in order to evaluate the interim results and
to infer about which AD to implement. In case of CT, where the
duration of treatment is extended or the effect of the therapy is
only measurable after a latency period, treatment withdrawal
will be more extensive because it is necessary to wait for the
results of the last patient included in order to ensure that there is
no overflow of the effects of this treatment.10
The first step is to choose the appropriate type of AD based
on the study objectives. In the case of a confirmatory trial
(phase III), a sequential group design or re-estimation of the
sample size may be considered. If the timing or number of the
interim analyses varies for practical reasons (eg, availability of
the data analysis commission [DAC] or safety issues require
additional interim analysis) and the estimation of the sample
size effect is unreliable, a group sequential design should be
used. If the number of doses (study arms) to be considered is
greater than 2 (including the control arm), and it is not known
exactly which dose (dosage or combination of medication) is
most appropriate, the “pick the winner” or “addition of study
arm” should be used.10
If a stable biomarker evaluation test is available (and is easy
to implement) and the experimental drug is expected to have
distinct effectiveness and/or safety profiles for subjects with
and without biomarker, a biomarker-enriched design can be
used in which the interim analysis will be used to select the
target population of the study.
In any scenario, a test simulation should be developed for
further evaluation and comparison of the operational charac-
teristics of the different designs or parameters of the trial
design. For an early-stage trial of a progressive disease, such
as cancer, an adaptive dose progression design is used in which
the dose is gradually increased according to the progression of
the disease so as to preserve patient safety and prevent the risk
of subdosing the therapy.11
The next step is to determine whether a superiority, non-
inferiority, or equivalence test is required on the basis of the
primary endpoint of the trial and the regulatory requirements,
and from that determine the number of interim analysis points.
The timing and number of interim analysis will be dependent
on safety requirements, statistical efficiency (more interim
analysis may reduce sample size), and feasibility (complexity
of trial development and associated costs).
Figure 3. Trials sponsor profile per therapeutic area (n ¼ 78).
Finally, practical factors have to be considered11:
– How long is the CT?
– Should the trial be suspended during the interim
analysis?
– When can the interim analysis and data cleaning be
carried out?
– Who will be responsible for carrying out the interim
review and drawing up the interim monitoring plan?
– How to perform randomization?
– How will the experimental drug be distributed by the
study centers?
– How will the primary analysis of adaptive trial data be
performed?
Adaptive Trial Planning
Given the complexity of adaptive trials and the predetermined
nature of any adaptation considered in their conduct, proper
planning is imperative. Like any other study, the protocol of a
CT has to be elaborated aiming at the rationale and the pri-
mary objectives that it is proposed to achieve. In addition to
the statistical challenges that are prioritized, operational
aspects also require prior evaluation. For example, timely
distribution of experimental drug in the centers should be
ensured, although preplanning is hampered by the difficulty
in predicting which dose will be maintained or discontinued
after interim analysis.12
The planning stage also includes the elaboration of the pro-
tocol, which is the key document in the structuring of the CT.
It is important to note that given the complexity of the meth-
ods and additional procedures performed in conducting an
AD, this will result in a more extensive and therefore
more complex protocol which requires that more elements
be included than in a standard test protocol. This includes the
justification for the application of an AD and the advantages
resulted from, based on the previous simulation of the trial. In
addition, a clear description of the adaptive mechanism
should be included, the role of the statistical analysis com-
mittee should be explained, and additional discussion related
to the control of type I error, its estimation calculations, and
error margins should be provided.12
In short, the planning stage of a CT with AD will be more
extensive than in a conventional trial. This is justified by the
preplanned nature of the implemented adaptations, and
the complexity of this type of study will also imply the alloca-
tion of more human and technical resources as multiple tasks
will be included in the initial preparation of the trial.
Trial Monitoring
The extent and nature of the monitoring is determined by the
CT sponsor, depending on the type of endpoints and the com-
plexity of the design of the study.
In a CT with AD, a DMC is defined that encompasses risk
management functions of the trial but also evaluates and
safeguards the statistical and scientific integrity of the CT.13
It consists of several independent experts assigned to the study
by the developer and can have access to unblinded data
throughout the trial to be able to formulate recommendations
on preplanned adaptations, focusing on the possibility of opera-
tional bias. Thus, standard operating procedures should be
defined at the beginning of the CT that have the ability to
minimize operational bias, that is, standardize procedures that
prevent the leakage of unblinded data.14
Because of the complexity of ADs, data quality is of great
importance to ensure that results are easily interpretable with-
out risk of ambiguity, requiring not only a well-trained research
team familiar with increased on-site monitoring but also
involves the use of electronic data collection (EDC). EDC
provides an opportunity to facilitate the management of results
and also speed up the cleaning of study data.14
Technical Considerations for Adaptive Design
The use of AD is very attractive because of its flexibility and
effectiveness in identifying clinical benefits of a treatment
tested, especially when limited resources and/or time are avail-
able. However, before an AD is implemented, the practical
aspects of applicability, validity, and robustness have to be
checked, which have an impact on the quality of the results
and integrity of the study.12
Concerning applicability, the following questions arise15:
– Do potential benefits outweigh the additional efforts
required to implement AD?
– Does the level of difficulty and costs associated with AD
justify the gains from its application?
– Does the implementation of AD delay the recruitment of
subjects and prolong the duration of the trial?
– How often are the unblinded analysis performed and to
whom is the concealment of the results to be broken?
For validity questions, it is reasonable to ask the following
questions:
– Can the break of concealment cause bias in the evalua-
tion of treatment effect?
– Can the implementation of AD affect randomization?
Subjects characteristics
The selection of study subjects should reflect the total popula-
tion for which the drug or device may be indicated. This is not
the case for studies in the early stages (phase I) when the choice
of subjects is influenced by research questions such as human
pharmacology. However, for confirmatory trials in later stages
(phase III), subjects should faithfully reflect the original patient
population. How much the CT subjects represent future users
can be influenced by the medical practices and standard treat-
ment level of a particular study center or geographic region.
The influence of these factors should be reduced and discussed
prior to analysis.16
Operational bias
Operational bias is a major source of concern in CT with AD.
Generally, in order to minimize it, it is necessary to control and
limit access to interim results of groups not blinded during the
trial. One way to achieve this is to restrict access by computer
coding of such data, which only releases its access at predeter-
mined times in the CT. This should happen if the sponsor
wishes to safeguard the possibility of suggesting scientifically
valid adaptations in the design of the trial in its course. In
addition, depending on the type of AD implemented, it is sug-
gested that the details of the statistical adaptation algorithm be
segregated from the protocol procedures in a SAP whose infor-
mation is forwarded to the data-monitoring committees, ethic
committees, and regulatory agencies. This contributes to the
scientific integrity of the CT and reduces the ability of external
observers to bias interim results based on the knowledge of
adaptations to the protocol.17
For a sequential AD, not all investigators involved must be
notified that an interim analysis has been performed. An inte-
grated analysis in the background ensures in parallel that the
trial follows the defined protocol and minimizes the bias asso-
ciated with the interim analysis. Similarly, a CT with adaptive
selection of a primary endpoint or adaptive change of hypoth-
esis, assuming that all variables are defined according to the
established protocol, the decision to change does not need to be
communicated to all study centers.
Well-documented control of study development information
increases the likelihood that the trial modifications will be
scientifically valid, maintain the integrity of the results gener-
ated, and their acceptance by regulatory authorities.18
Statistical Considerations for Adaptive Design
From a statistical point of view, significant adaptations or mod-
ifications to the CT and/or statistical procedures may (1) result
in a deviation in pharmacotherapeutic parameters in the target
population, (2) lead to inconsistencies between hypotheses to
be tested and their matching statistical tests, and (3) introduce
operational bias/variation in data collection.
The sources of bias/variation can be classified into 4
categories19:
– Expectable and controllable, such as changes in labora-
tory testing procedures and/or diagnostic procedures
– Expectable but not controllable, such as change in study
dose and/or duration of treatment
– Not expected but controllable, such as lack of compli-
ance of subjects with the study
– Unexpected and uncontrollable, those are the random
errors in observing clinical responses/outcomes
Simulation and modeling of the trial
As noted above, any adaptation implemented in a CT must be
pre-established. Consistent with this premise, the design of
the trial is tested prior to the definition of the final design
model used.
The CT simulation is a structural approach that mimics all
the procedures and methods inherent in conducting a CT and
allows determining the influence of the parameters of the test
design model used in the results generated. It assists in under-
standing the impact that any adaptation will produce on the
scientific and statistical validity of the CT as well as on its
development.20
Computer-generated simulations can provide the opera-
tional characteristics of the study design in different scenarios.
These simulations can evaluate different scenarios with a vari-
able number and timing of interim analysis and can be used to
weigh the advantages and disadvantages of different ADs, or an
AD compared to a nonadaptive design. They may also provide
additional understanding of the required sample size, opera-
tional characteristics, and correlate the design of the trial with
patient characteristics when it cannot be performed with an
analytical method.22
Computational simulations have limitations. First, its use-
fulness and quality are dependent on the ability to design rea-
listic scenarios. Second, simulation programming errors can be
difficult to detect, which may lead to choices of test designs
that are not appropriate. Third, complex trial designs that
involve multiple endpoints or a complicated null hypothesis
detection range may be difficult to simulate.21
Modeling plays an important role in the characterization of
alternative scenarios, such as the process of patient recruitment
and abandonment, dose-response profiles, and endpoint corre-
lation. The combination of modeling and simulation is the axis
for the evaluation and comparison of alternative designs for the
study, including AD, as well as the planning of a specific type
of AD (eg, number and timing of adaptations, impact on rate
and power of type I error).
The FDA guidelines for the implementation of AD recog-
nize the importance of CT simulation for establishing the
operational characteristics of AD, comparing alternative
designs to justify the selection of a specific design and under-
standing the deductive properties of AD. Therefore, the guide-
lines attest that adaptive CT simulation notification should be
an important component in documentation submitted to the
FDA when a sponsor proposes the use of an AD in a developing
trial. This document describes in detail the types of design that
can be considered in assessments based on simulations of adap-
tive tests as well as all the elements that should be described
when notifying an adaptive CT simulation.14
Given the complexity of the CT with AD, the simulation of
the trial is very important to define how each adaptive model
will affect the type I error rate, study power, and degree of bias,
being required by regulatory agencies that the test information
resulting from the CT simulation be reported on the study
protocol.21
Protocol and statistical analysis plan
Given the possible existence of sources of operational bias
that unhinges the integrity of an adaptive CT, the prospec-
tive specifications in the protocol of all aspects of the study
design and scheduled analyses are of paramount importance.
Thus, an adaptive trial protocol is typically more complex
and detailed than in a standard trial. The protocol and asso-
ciated documentation (such as the simulation report) must
contain critical information that allows regulatory agencies
to assess the implementation of AD, such as the
following12:
– Rationale of the study
– Justification of the design template, including proposed
adaptations
– Operational characteristics of the proposed design and
type I error rate
– Plan ensuring trial integrity when planning unblinded
interim analyses
– Role of AD in CT development strategy
– Objectives of the proposed AD, all possible adjusted
adaptations, assumptions, methodology analysis, and
quantitative justification of the test design options taken
(via simulation)
– Impact of adaptations on the operational characteristics
of the trial (eg, type I error rate)
– Summary of models used in planning (eg, disease pro-
gression, dropout, dose-response)
– Analytical derivations that demonstrate strict control of
type I error rate
– List of professionals involved in the planning and imple-
mentation of adaptations and monitoring of the trial
As one of the main features of CTs with AD is the pre-
established nature of the adaptations introduced, it is recom-
mended that an autonomous statistical analysis committee be
elaborated with an SAP that prospectively includes all the sta-
tistical treatment of the planned adaptations that will be
detailed in the protocol.12
At the end of the drafting of the protocol, the SAP will not
only ensure that the statistical procedures resulting from the
implemented adaptations are correct and apt to be used during
the trial, but also provide an opportunity for the study sponsor
to gain regulatory agreement on the adaptive design and asso-
ciated statistical analysis.
Another aspect of AD is that the implementation of adapta-
tions occurs without affecting the scientific integrity of the
study. An early establishment of an SAP will also contribute
to demonstrate that the operational bias, which is noteworthy in
unblinded interim analysis, is not relevant as the statistical
treatment of the data is predefined prior to the first interim
analysis.22
Specific elements should include the SAP, which are the
following22:
– All adaptations planned prospectively
– Statistical methods that will be used in the implemented
adaptations (eg, how to calculate a potential increase in
sample size or duration of the test, rule used to select the
dose administered)
– Justification for assessing the type I error rate
– Statistical approach to be used to determine therapeutic
results
General Limitations of Adaptive Design
The use of AD in a CT for the purpose of modifying its
analytical and statistical procedures, based on interim accu-
mulated data, has been practiced for several years in clinical
research. Adaptive methodologies are very appealing to clin-
ical investigators for several reasons. First, it reflects clinical
practice in an investigational context. Second, it respects ethi-
cal paradigms related to the efficacy and safety (toxicity) of
the experimental drug under study. Third, it is not only flex-
ible but also efficient in early stages of clinical development.
However, questions are raised regarding the reliability of the
P values of the parameters determined and their confidence
intervals (Table 3). In addition, the systematic use of adaptive
methodologies can bias the basic rationale of the study, which
would make the clinical trial incapable of addressing the pri-
mary goals it intends to achieve.23
Regulatory limitations
From the regulatory point of view, the FDA is supportive of AD
although factors defining appropriative implementation are still
being worked out. Adaptive trials are reviewed on a case-by-
case basis, with caution from sponsors that protocols using
innovative approaches are rejected, leading to delays in the
approvals. Given the limited experience of the pharmaceutical
industry but also regulatory authorities related to adaptive test-
ing, there may be reservations in accepting the scientific valid-
ity of such trials. This may be because there are still no
universally accepted statistical methods for all possible adapta-
tions. Thus, in certain cases, clear statistical inferences cannot
be produced, which makes the regulatory authorities approval
process difficult, if not impossible.24
The fear that the use of the interim analyses to inform design
adjustments may cause bias and put the statistical validity of
the CT at risk is frequent, but this level of anxiety is reduced as
the knowledge in the application of AD accumulates. Thus,
concealment procedures should be standardized prior to the
start of the trial.24
Logistic limitations
The implementation and conduction of an adaptive trial cre-
ates a number of logistical challenges. A robust infrastructure
must be established to ensure that the AD is implemented
correctly. All parties involved in the coordination and moni-
toring of the trial (sponsor, patients, and investigative team as
a whole) should have an integrated understanding of the
principles of the implemented AD. Interim changes and adap-
tations in the sample size, objectives, endpoints, or reference
values may represent obstacles in the temporal availability of
physical resources (physical space that includes all additional
procedures), technical (extra equipment required), budget (to
cover additional costs to patients in case of extra randomiza-
tion or treatment allocation procedures), human (if it is nec-
essary to increase the research team because extra procedures
are introduced), and statistical tools affecting the quality of
the test results.23
Various types of adaptations allow treatment arms or doses
to be discontinued, more patients to be allocated to a specific
treatment arm, or the total sample size recalculated after
an interim analysis, making it difficult to prospectively plan
the supply of experimental drug to all study centers in ade-
quate amounts.25
General Advantages of Adaptive Design
The FDA’s “Clinical Path Opportunities List” lists one of the
major advantages of AD with its ability to accelerate the pro-
cess of developing and approving new drugs. This arises from
the possibility of combining distinct phases of clinical investi-
gation or include experimental features in confirmatory trials.
The combination of phases in a seamless phase II/III design not
only streamlines the conduct of the test (in two distinct phases)
but also simplifies the submission and approval process as the
two phases are involved in the same submission to the regula-
tory authorities.27 Streamlining the clinical development of a
new drug also implies that an effective new treatment can be on
the market faster, so it will be accessible to patients sooner.
For the pharmaceutical industry, this means that a larger fraction
of the patent for a compound is valid when the drug enters the
market, which allows a higher return on the investment made.
Another advantage is the flexibility that the AD confers to
a CT. For example, if an adaptation is planned prospectively,
several characteristics of the study design can be modified
based on interim results, which is impossible in a conven-
tional trial frame because of the rigid setting of a conventional
design model.26
If properly conducted and statistical inference is assured,
adaptive trials may also be considered more ethical. The goal
of any adaptive trial is to accelerate the clinical development
process, which results in fewer patients having to be exposed to
an experimental treatment by early discontinuation of an inef-
fective treatment arm, by changing the inclusion criteria during
the trial for those who are more likely to benefit from treat-
ment, reduction of sample size or termination of an early trial
for futility, efficacy, or toxicity are included. As already men-
tioned, this not only implies that fewer patients are exposed to
ineffective treatments but also that those treatments that are
effective and safe reach the population more quickly.27
Overall, the possible benefits of using adaptive design meth-
ods in a CT include the following27:
– allows the investigator to correct erroneous assumptions
made at the beginning of the CT;
– helps select the most promising therapeutic option dur-
ing the course of the trial;
– provides the opportunity to react in advance to new
pieces of information (positive or negative);
– can shorten the development time of the CT and, con-
sequently, accelerate the overall process of developing
the new drug.
Future Perspectives of Adaptive Design in Clinical Trials
In recent years, there has been an evolution in the orientation
of the pharmaceutical industry toward the need to strengthen
Table 3. Challenges and Limitations Associated With Specific Types of Adaptation.
Type of Adaptive Design Challenge/Limitation
Adaptive randomization – Randomization pattern only determined after CT start
– Difficulty in applying in a broad CT or when treatment duration is extended
– Difficult to formulate statistical inferences in treatment effect
Sample size re-estimation – May lead to unwanted exposure to interim results: operational bias
Adaptive dose
progression
– Determination of initial dose and dose range tested
– Achieve statistical significance with predictive power, despite the reduced number of patients
– Manage CT supplies to study centers
Change in the eligibility
criteria
– Change in target population
– Difficult to assess results when multiple changes (the estimation of the treatment effect in a subpopulation, to
which population the results are applicable?)
Phase II/III “seamless” – Inflation rate type I
– Difficult estimation of sample size and patient allocation
– Combined analysis is difficult when endpoints are distinct for each phase
Change in study objective – Determination of the non-inferiority margin
– Sample size estimation
Endpoint adaptation – Risk of selecting an inappropriate endpoint if interim results show sensitivity variability between different
endpoints
clinical research as well as a general perception that this sec-
tor needs to follow the evolution that the activity has experi-
enced recently.
For the pharmaceutical industry, the use of AD will allow
more doses to be tested in phases I and II, leading to a better
understanding of the effect of the drug on patients at doses that
are clinically relevant, leading to better drug development deci-
sions and, for successful drugs, a better phase III trial design,
thus helping to reduce the failure of a drug at this stage or,
worse, at a later stage of its development. An uninterrupted
phase I and phase IIa study will allow efficiency and toxicity
to be studied from the start of the CT, with the safety study
directly from healthy volunteers. This uniformity will allow the
CT to be stopped early if the compound is ineffective or allow
it to continue with additional dose arms.28
The AD promotes early communication between regulatory
agencies and sponsors ensuring more robust study designs. A
more constructive collaboration between regulatory agencies,
industry, and research centers in the form of consortia will
make it more agile, allowing the development of treatment
options for pathologies with few therapeutic options, for exam-
ple, for rare diseases.
For patients, AD will minimize exposure to potentially
harmful and ineffective experimental treatments, improve
understanding of the disease process and expedite visitation
schedules and/or dose regimens.
In the future, it is suggested that the impetus to apply AD to
CT be made with caution, since this methodology is not a “one
size fits all,” that is, its application is not feasible nor desirable
in all the phases of clinical research and in all therapeutic areas.
It is advisable to assess the feasibility and the benefits of apply-
ing AD on a case-by-case basis, but also a consideration of the
resources (human, budgetary, logistic) necessary for the correct
application of this methodology in each study center.29
Updated FDA Draft Guidance 2018
The new adaptive designs draft guidance replaces the earlier
draft guidance issued in 2010. The new draft guidance reflects
an evolution in FDA’s thinking in acknowledging the potential
adverse impact arising from type I error and in eliminating
confusing categorization of “well understood” and “not well
understood” adaptive design methods in favor of a more
focused assessment of factors, such as unblinding, that can
increase risk of bias.
The draft features discussions on limitations of adaptive
trials, how to control the chance for erroneous conclusions,
estimating treatment effects, ADs based on comparative data
vs noncomparative data and adaptations to the subject
population.
Under the special considerations section, the draft also dis-
cusses simulations in adaptive design planning, Bayesian adap-
tive designs, adaptations in time-to-event settings, adaptations
based on a potential surrogate or intermediate endpoint, sec-
ondary endpoints, adaptive design in early-phase exploratory
trials, unplanned design changes based on comparative interim
results, and design changes based on information from a source
external to the trial.30
Conclusions
When EMA and the FDA published their AD documents in
2007 and 2010, much hope has been placed in these types of
CT design to optimize and accelerate the development of new
drugs. However, since these adaptive methods are not appli-
cable at all stages and only in specific situations in certain
CTs (in terms of sample size, type of endpoints, duration of
the CT), their use has only been shown to be advantageous in
CTs with an immediate therapeutic effect (allowing the col-
lection of interim efficacy and safety data), with limited num-
ber of sites or clinical trials where data cleaning can be easily
carried out, which is far short of the pharmaceutical industry
investment in this sector. However, many authors suggest that
the use of AD in CTs has several advantages compared with
conventional trials.
If properly planned and properly conducted, it can be seen as
an opportunity for both the pharmaceutical industry and the
regulatory authorities to optimize the overall duration of the
development of a medicinal product and allow a faster access
of the patient population to new therapeutic solutions.
The Tufts Center for the Study of Drug Development esti-
mates that around 20% of CTs currently under way are using
adaptive designs, while adoption of these techniques is likely to
increase significantly over the next few years, particularly in
the exploratory phase of drug development. The same study
reports that early study terminations due to futility and sample
size re-estimation could save sponsor organizations between
$100 million and $200 million annually in aggregate costs.31,i
Adaptive trials should not be viewed as solutions to poorly
planned trials. Potential sources of bias should be considered as
well as how well the cumulative results of the CT will be
properly interpreted and aligned with the primary purpose of
the study, the ethical and scientific requirements of the regula-
tory authorities, and the strategic interests of the sponsor.
Alternatives, whether adaptive or nonadaptive, should be
considered, and it should be demonstrated that the selected
adaptation has tangible advantages over other options, whether
ethical treatment of patients, time and/or resource savings, and
better quality of the results and information produced by the
CT. The control of the type I error rate (false positive rate) is
the main objective of the statistical methodology used (espe-
cially in confirmatory tests), so the degree of success will
determine the validity of the inferences and results produced.
Logistical problems related to the supply of experimental
drugs in different study centers (in the case of administering
different doses of the experimental drug), resource allocation,
information circulation, and communication may be more chal-
lenging constraints than in a conventional clinical trial. The
infrastructure of the adaptive design must be arranged in such
a way that the flow of information is processed without delays
that have an impact on the efficiency of the CT. Instructions on
efficient data collection, database preparation, decision mak-
ing, communication and delegation of tasks, and analysis and
review of results should be established in advance in order to
reinforce the predetermined nature of the AD.
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8. Elsäßer A, Regnstrom J, Vetter T, et al. Adaptive clinical trial
designs for European marketing authorization: a survey of scien-
tific advice letters from the European Medicines Agency. Trials.
2014;15(1):383.
9. Brannath W, Burger HU, Glimm E, Stallard N, Vandemeuleb-
roecke M, Wassmer G. Comments on the draft guidance on
“adaptive design clinical trials for drugs and biologics” of the
US Food and Drug Administration.” J Biopharm Stat. 2010;
20(6):1125-1131.
10. Quinlan A, Krams M. Implementing adaptive designs: logistical
and operational considerations. Therapeutic Innovation & Regu-
latory Science. 2006;40(4):437-444.
11. Wang SJ.Regulatory experience of adaptive designs in well-
controlled clinical trials. Paper presented at: Adaptive Designs:
Opportunities, Challenges and Scope in Drug Development,
Washington, DC, 2006.
12. Gallo P, Maurer W. Challenges to implementing adaptive
designs: comments on the viewpoints expressed by regulatory
biostatisticians. Biom J. 2006;48(4):591-597.
13. Baber N. International Conference on Harmonization of Techni-
cal Requirements for Registration of Pharmaceuticals for Human
Use (ICH). Br J Clin Pharmacol. 1994;37(5):401-404.
14. Tsiatis A, Mehta C. On the inefficiency of the adaptive design for
monitoring clinical trials. Biometrika. 2003;90(2):367-378.
15. Hu F, Rosenberger WF. Optimality, variability, power: evaluating
response-adaptive randomization procedures for treatment com-
parisons. J Am Stat Assoc. 2003;98:671-678.
16. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin
Oncol. 2011;9(4):199-207.
17. Lavori PW, Dawson R. A design for testing clinical strategies:
biased adaptive within-subject randomization. J R Stat Soc. 2000;
163(1):29-38.
18. Tsiatis AA. Information based monitoring of clinical trials. Stat
Med. 2006;25:3236-3244.
19. Kieser M, Friede T. Re-calculating the sample size in internal
pilot study designs with control of the type I error rate. Stat Med.
2000;19:901-911.
20. Li HI, Lai PY. Clinical trial simulation. In: Chow SC, ed. Ency-
clopedia of Biofarmaceutical Statistics. New York, NY: Marcel
Dekker, Inc; 2003:200-201.
21. Holford NHG, Kimko HC, Monteleone JPR, et al. Simulation
of clinical trials. Annu Rev Pharmacol Toxicol. 2000;40:
209-234.
22. Hung HMJ, Wang SJ, O’Neill R. Statistical considerations for
testing multiple endpoints in group sequential or adaptive clinical
trials. J Biopharm Stat. 2007;17(6):1201-1210.
23. Triphaty V. Adaptive clinical trials: challenges and opportunities.
www.tcs.com/SiteCollectionDocuments/White%20Papers/LS-
WhitePaper-Adaptive-clinical-trials-challenges-opportunites-
0713%20-1.pdf. Published 2013. Accessed January 22, 2018.
24. Hung HM, O’Neill RT, Wang SJ, Lawrence J. A regulatory view
on adaptive/flexible clinical trial design. Biom J. 2006;48(4):
565-573.
25. Chow SC, Shao J. Inference for clinical trials with some protocol
amendments. J Biopharm Stat. 2005;15:659-666.
26. Woodcock J, Woosley R. The FDA critical path initiative and its
influence on new drug development. Annu Rev Med. 2008;59:1-12.
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